Oxidative stress in anticancer therapies-related cardiac dysfunction
- 1 June 2021
- journal article
- research article
- Published by Elsevier BV in Free Radical Biology & Medicine
- Vol. 169, 410-415
- https://doi.org/10.1016/j.freeradbiomed.2021.04.021
Abstract
No abstract availableFunding Information
- Amgen
- Alere
This publication has 81 references indexed in Scilit:
- Creatine Kinase-Overexpression Improves Myocardial Energetics, Contractile Dysfunction and Survival in Murine Doxorubicin CardiotoxicityPLOS ONE, 2013
- Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced CardiotoxicityScience Translational Medicine, 2013
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Modulation of Anthracycline-Induced Cardiotoxicity by Aerobic Exercise in Breast CancerJournal of the American College of Cardiology, 2011
- Reduced in vivo high-energy phosphates precede Adriamycin-induced cardiac dysfunctionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- The Vulnerability of the Heart As a Pluricellular Paracrine OrganCirculation Research, 2010
- Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein KinaseClinical and Translational Science, 2009
- Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent PathwaysOnline Journal of Public Health Informatics, 2009
- Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the HeartScience, 2008
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007